查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1818412

新型分子實體藥物市場報告：2031 年趨勢、預測與競爭分析

New Molecular Entity Drug Market Report: Trends, Forecast and Competitive Analysis to 2031
出版日期: | 出版商: Lucintel | 英文 150 Pages | 商品交期: 3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

全球新型分子實體藥物市場前景光明，得益於醫院診所市場的機會。預計2025年至2031年期間，全球新型分子實體藥物市場的複合年成長率將達到5.1%。該市場的主要驅動力是全球慢性病負擔的增加以及藥物研發投入的增加。

  • Lucintel 預測小分子藥物將在預測期內經歷最高的成長率。
  • 按使用類型來看，醫院預計將實現最高成長。
  • 按地區分類，預計亞太地區將在預測期內實現最高成長。

新分子實體藥物市場新趨勢

新型分子實體藥物市場正受到多種新興趨勢的影響，包括技術進步、法規結構的演變以及對個人化醫療的日益重視。這些趨勢正在影響新藥的開發、核准和交付給患者的方式。

  • 個人化醫療：個人化醫療是新分子醫學（NME）製藥市場的關鍵趨勢，其重點越來越在於根據個人基因圖譜和疾病特徵制定個人化治療方案。這種方法透過靶向疾病的根本病因來提高治療效果，尤其是在腫瘤和罕見遺傳疾病領域。因此，製藥公司正在大力投資精準醫療、生物標記研究和伴隨診斷，以開發標靶治療。個人化治療也有助於最大限度地減少副作用，並改善患者的治療效果和滿意度。
  • 加速藥品核准：為了滿足尚未滿足的醫療需求，包括美國、中國和日本在內的許多國家正在對此類治療方案實施加速核准。 FDA 的突破性療法認定和 EMA 的 PRIME 計劃等舉措旨在加快有前景的嚴重治療藥物的核准流程。這些監管改革縮短了新藥上市時間，加快了創新治療方法的可及性，並更有效地應對了全球健康挑戰，使患者和製藥公司都受益。
  • 生技藥品和基因療法：生技藥品和基因療法的蓬勃發展正在改變新分子實體藥物市場，為曾經被認為無法治癒的疾病提供了新的治療選擇。包括單株抗體、疫苗和重組蛋白生技藥品在癌症、自體免疫疾病和遺傳性疾病的治療中越來越受歡迎。基因療法有望在分子層面上糾正基因突變，為以往無法治癒的疾病提供長期解決方案。這種轉變正在擴大新分子實體藥物市場的範圍，並為生技藥品和基因療法領域的公司創造新的機會。
  • 人工智慧 (AI) 與機器學習的融合：AI 和機器學習正逐漸融入新分子實體 (NME) 藥物研發流程。這些技術正在幫助研究人員分析大量資料集、識別新的藥物標靶，並比傳統方法更有效率地預測化合物療效。 AI 也被用於設計臨床試驗，從而提高成功率並降低成本。隨著 AI 技術的發展，其在藥物研發中的應用有望縮短上市時間，並使針對多種疾病的標靶治療更加成功。
  • 聚焦罕見疾病：人們越來越重視開發用於治療罕見疾病和孤兒疾病的新分子實體，因為這些疾病通常缺乏有效的治療方法。這一趨勢受到孤兒藥認定等監管激勵措施以及對這些疾病分子機制研究的不斷加強的推動。製藥公司意識到，滿足這些患者群體尚未滿足的需求，具有巨大的科學和商業性成功潛力。隨著基因療法、生技藥品和個人化醫療的進步，NME藥物擁有改變罕見疾病治療格局的巨大潛力。

這些趨勢正在改變新分子實體（NME）製藥市場，加速創新治療方法的開發和核准，提高治療精準度，並擴大罕見疾病新療法的可及性。個人化醫療、更快的監管核准以及人工智慧的應用正在幫助簡化藥物開發流程，而生技藥品和基因療法則為以往無法治癒的疾病提供了突破性的解決方案。隨著這些趨勢的不斷發展，它們將重塑製藥格局，改善患者治療效果並推動市場成長。

新分子實體藥物市場的最新趨勢

最近的趨勢表明，幾項關鍵發展正在塑造新型分子化合物市場，推動創新並改善患者護理。

  • 突破性癌症療法核准新型分子化合物市場近期最重大的進展之一是多項突破性癌症療法的核准，尤其是在免疫腫瘤學領域。免疫查核點抑制劑和嵌合抗原受體-T細胞療法等療法徹底改變了多種癌症的治療方式。這些治療方法利用人體免疫系統對抗癌症，為晚期或難治性癌症患者帶來希望。這些創新治療方法的核准標誌著腫瘤學新時代的到來，實驗室測試已取得令人鼓舞的成果，並在臨床中廣泛應用。
  • mRNA疫苗的進展：COVID-19疫情凸顯了mRNA技術不僅在疫苗領域的潛力，也體現在開發新型分子實體。 Moderna和輝瑞等公司率先推出了mRNA疫苗技術，目前正探索將其應用於其他疾病，包括癌症和罕見遺傳疾病。 mRNA疫苗的成功為NME藥物開發開闢了新的途徑，使得在分子層面上快速生產和客製化針對特定疾病的治療方法成為可能。
  • 專注於阿茲海默症治療：為了滿足日益成長的神經退化性疾病治療需求，大量投資和研究已投入用於治療阿茲海默症的NME藥物的開發中。近年來，一些旨在減緩阿茲海默症進展的新型分子實體（例如抗澱粉樣BETA蛋白療法）應運而生。雖然其中一些治療方法仍處於早期階段，但它們的核准將代表阿茲海默症症治療方法邁出的一大步，該疾病長期以來一直缺乏有效的治療方法。
  • 增加對生技藥品的投資：生技藥品正成為製藥公司開發新分子實體（NME）日益重要的焦點。隨著生技藥品在新藥認證中的佔比不斷上升，各公司正在擴展其產品線，涵蓋單株抗體、基因療法和重組蛋白。對生技藥品的關注預計將推動NME藥物市場的發展，尤其是在癌症、自體免疫疾病和罕見遺傳疾病領域。生技藥品的興起也推動了製造和給藥方法的進步，從而提高了這些高成本治療的可近性。
  • 加速藥品核准的監管改革：包括美國食品藥物管理局 (FDA)、歐洲藥品管理局 (EMA) 和國家藥品監督管理局 (NMPA) 在內的主要市場監管機構已實施多項舉措，以加速新藥核准。快速通道、突破性療法認定和優先審查資格使有前景的新藥能夠更快地進入市場。這些監管改革使患者能夠更快地獲得創新治療方法，縮短了重要治療方法在全球範圍內上市的時間，並促使製藥公司競相開發下一代藥物。

新興市場近期的趨勢正在加速創新，尤其是在腫瘤學、神經病學和罕見疾病領域。突破性治療方法的核准、mRNA技術的進步以及生技藥品的興起，正在為全球患者拓展治療選擇。監管改革也加速了新治療方法的上市進程，使尚未滿足的醫療需求更有效率。這些發展正在透過提高新治療方法治療複雜疾病的速度和精準度，重塑新藥市場。

目錄

第1章執行摘要

第2章 市場概況

  • 背景和分類
  • 供應鏈

第3章：市場趨勢及預測分析

  • 宏觀經濟趨勢與預測
  • 產業驅動力與挑戰
  • PESTLE分析
  • 專利分析
  • 法規環境

4. 全球新型分子實體藥物市場（按類型）

  • 概述
  • 按類型進行吸引力分析
  • 抗體：趨勢與預測（2019-2031）
  • 多肽：趨勢與預測（2019-2031）
  • 小分子藥物：趨勢與預測（2019-2031）
  • 其他：趨勢與預測（2019-2031）

5. 全球新分子實體藥物市場（依應用）

  • 概述
  • 按用途進行吸引力分析
  • 醫院：趨勢與預測（2019-2031）
  • 診所：趨勢與預測（2019-2031）

第6章 區域分析

  • 概述
  • 區域新型分子實體藥物市場

7. 北美新型分子實體藥物市場

  • 概述
  • 北美新型分子實體藥物市場（按類型）
  • 北美新型分子實體藥物市場（按應用）
  • 美國新型分子實體藥物市場
  • 墨西哥新型分子實體藥物市場
  • 加拿大新型分子實體藥物市場

8. 歐洲新型分子實體藥物市場

  • 概述
  • 歐洲新型分子實體藥物市場（按類型）
  • 歐洲新型分子實體藥物市場（依應用）
  • 德國新型分子實體市場
  • 法國新型分子實體市場
  • 西班牙新型分子實體市場
  • 義大利新型分子實體市場
  • 英國新型分子實體藥物市場

9. 亞太地區新型分子實體藥物市場

  • 概述
  • 亞太地區新型分子實體藥物市場（按類型）
  • 亞太地區新型分子實體藥物市場（依應用）
  • 日本新分子化合物藥物市場
  • 印度新型分子實體藥物市場
  • 中國新分子實體藥物市場
  • 韓國新分子實體藥物市場
  • 印尼新型分子實體藥物市場

10. 世界其他地區新分子實體藥物市場

  • 概述
  • 世界其他地區新分子實體藥物市場（按類型）
  • 世界其他地區新分子實體藥物市場（按應用）
  • 中東新型分子實體藥物市場
  • 南美洲新型分子實體藥物市場
  • 非洲新型分子實體藥物市場

第11章 競爭分析

  • 產品系列分析
  • 營運整合
  • 波特五力分析
    • 競爭對手之間的競爭
    • 買方的議價能力
    • 供應商的議價能力
    • 替代品的威脅
    • 新進入者的威脅
  • 市佔率分析

第12章：機會與策略分析

  • 價值鏈分析
  • 成長機會分析
    • 按類型分類的成長機會
    • 按應用分類的成長機會
  • 全球新分子實體藥物市場的新趨勢
  • 戰略分析
    • 新產品開發
    • 認證和許可
    • 合併、收購、協議、合作和合資企業

第13章 價值鏈主要企業的公司簡介

  • 競爭分析
  • UCB
  • Otsuka Pharmaceutical
  • Eli Lilly
  • Genentech
  • Eisai
  • Biogen
  • Menarini Group
  • GSK
  • Chest
  • Travere

第14章 附錄

  • 圖表目錄
  • 表格一覽
  • 調查方法
  • 免責聲明
  • 版權
  • 簡稱和技術單位
  • 關於我們
  • 聯絡處

The future of the global new molecular entity drug market looks promising with opportunities in the hospital and clinic markets. The global new molecular entity drug market is expected to grow with a CAGR of 5.1% from 2025 to 2031. The major drivers for this market are the increasing global burden of chronic conditions and the growing investments in pharmaceutical research.

  • Lucintel forecasts that, within the type category, small molecule drugs are expected to witness the highest growth over the forecast period.
  • Within the application category, hospitals are expected to witness the highest growth.
  • In terms of region, APAC is expected to witness the highest growth over the forecast period.

Emerging Trends in the New Molecular Entity Drug Market

The new molecular entity drug market is being shaped by several emerging trends, including technological advancements, evolving regulatory frameworks, and increased focus on personalized treatments. These trends are impacting how new drugs are developed, approved, and delivered to patients.

  • Personalized Medicine: Personalized medicine is a key trend in the NME drug market, with an increasing focus on tailoring treatments based on individual genetic profiles and disease characteristics. This approach improves the efficacy of treatments by targeting the underlying causes of diseases, especially in oncology and rare genetic disorders. As a result, pharmaceutical companies are investing heavily in precision medicine, biomarker research, and companion diagnostics to develop targeted therapies. Personalized treatments also helps to minimize side effects and improve patient outcomes and satisfaction.
  • Accelerated Regulatory Approvals: To address unmet medical needs, many countries, including the U.S., China, and Japan, are implementing faster regulatory pathways for NME drugs. Initiatives like the FDA's Breakthrough Therapy Designation and the EMA's PRIME program are designed to expedite the approval process for drugs that show significant promise in treating serious conditions. These regulatory changes are reducing the time it takes for new drugs to reach the market, benefiting both patients and pharmaceutical companies by speeding up access to innovative therapies and addressing global health challenges more efficiently.
  • Biologics and Gene Therapy: The increasing use of biologics and gene therapies is transforming the NME drug market, as these therapies offer new treatment options for diseases that were once considered untreatable. Biologics, which include monoclonal antibodies, vaccines, and recombinant proteins, are becoming more prevalent in treating cancer, autoimmune diseases, and genetic disorders. Gene therapies are offering the potential to correct genetic mutations at the molecular level, providing long-term solutions for previously incurable conditions. This shift is expanding the scope of the NME drug market, creating new opportunities for companies in the biologics and gene therapy space.
  • Integration of Artificial Intelligence (AI) and Machine Learning: AI and machine learning are increasingly being integrated into the NME drug discovery process. These technologies are helping researchers analyze large datasets, identify new drug targets, and predict the effectiveness of compounds more efficiently than traditional methods. AI is also being used to design clinical trials, improving the likelihood of success and minimizing costs. As AI technology evolves, its application in drug discovery and development is expected to reduce time-to-market and lead to more successful, targeted therapies for a range of diseases.
  • Focus on Rare Diseases: There is a growing emphasis on developing new molecular entities to treat rare and orphan diseases, which often lack effective treatments. This trend is being driven by regulatory incentives, such as orphan drug designations, and increased research into the molecular mechanisms of these diseases. Pharmaceutical companies are recognizing the potential for both scientific and commercial success in addressing unmet needs in this underserved patient population. With advancements in gene therapies, biologics, and personalized medicine, there is significant potential for NME drugs to transform the treatment landscape for rare diseases.

These trends are revolutionizing the NME drug market by accelerating the development and approval of innovative therapies, improving the precision of treatments, and expanding access to novel treatments for rare diseases. Personalized medicine, accelerated regulatory approvals, and the use of AI are helping streamline the drug development process, while biologics and gene therapy are providing groundbreaking solutions for previously untreatable conditions. As these trends continue to evolve, they will reshape the pharmaceutical landscape, improving patient outcomes and driving market growth.

Recent Developments in the New Molecular Entity Drug Market

Several key developments have been shaping the new molecular entity drug market, driving innovation, and improving patient care in recent years.

  • Approval of Breakthrough Cancer Therapies: One of the most significant recent developments in the NME drug market is the approval of several breakthrough cancer therapies, particularly in immuno-oncology. Drugs like immune checkpoint inhibitors and CAR T-cell therapies have revolutionized the treatment of various cancers. These therapies harness the body's immune system to fight cancer, offering hope for patients with advanced or refractory cancers. The approval of these innovative treatments has marked a new era in oncology, with promising results in clinical trials and growing adoption in clinical settings.
  • Advances in mRNA-Based Vaccines: The COVID-19 pandemic highlighted the potential of mRNA technology, not only for vaccines but also for developing new molecular entities. Companies like Moderna and Pfizer have been pioneers in mRNA vaccine technology, and this approach is now being explored for other diseases, including cancer and rare genetic disorders. The success of mRNA vaccines has opened new avenues for NME drug development, allowing for rapid production and customization of therapies to target specific diseases at the molecular level.
  • Focus on Alzheimer's Disease Treatments: There has been significant investment and research into developing NME drugs for Alzheimer's disease, driven by the growing need for treatments for neurodegenerative disorders. In recent years, several new molecular entities aimed at slowing the progression of Alzheimer's have received attention, including anti-amyloid beta therapies. While some of these therapies are still in the early stages, their approval would represent a major step forward in treating Alzheimer's, which has long lacked effective therapeutic options.
  • Increased Investment in Biologics: Biologics are increasingly becoming a key focus of pharmaceutical companies developing NMEs. With biologics accounting for a growing share of new drug approvals, companies are expanding their pipelines to include monoclonal antibodies, gene therapies, and recombinant proteins. This focus on biologics is expected to drive the NME drug market forward, particularly in the areas of oncology, autoimmune diseases, and rare genetic disorders. The rise in biologics has also spurred advances in manufacturing and delivery methods, improving the accessibility of these high-cost treatments.
  • Regulatory Changes to Speed Drug Approvals: Regulatory agencies in key markets, such as the FDA, EMA, and NMPA, have implemented several initiatives to expedite the approval of NMEs. Fast Track Designations, Breakthrough Therapy Designations, and Priority Review designations have allowed promising new drugs to reach the market more quickly. These regulatory changes are enabling patients to access innovative therapies sooner, reducing the time it takes for critical treatments to be available globally, and driving competition among pharmaceutical companies to develop the next generation of NME drugs.

Recent developments in the NME drug market have accelerated innovation, particularly in oncology, neurology, and rare diseases. The approval of breakthrough therapies, advances in mRNA technology, and the rise of biologics are expanding treatment options for patients worldwide. Regulatory changes have also sped up the process of getting new treatments to market, addressing unmet medical needs more efficiently. These developments are reshaping the NME drug market, improving the speed and precision with which new therapies are introduced to address complex diseases.

Strategic Growth Opportunities in the New Molecular Entity Drug Market

The new molecular entity drug market presents several strategic growth opportunities across various applications, with increasing demand for targeted and personalized therapies.

  • Oncology Treatments: The oncology segment remains one of the most significant growth opportunities in the NME drug market. New molecular entities are revolutionizing cancer treatment, particularly through immunotherapy, targeted therapies, and personalized medicine. As cancer continues to be a leading cause of death worldwide, the demand for effective and innovative cancer treatments is high. Pharmaceutical companies are investing heavily in developing NMEs to address unmet needs in oncology, especially for rare and difficult-to-treat cancers.
  • Rare and Orphan Diseases: There is a growing focus on developing NMEs for rare and orphan diseases, which often have limited treatment options. Regulatory incentives such as orphan drug designations are encouraging pharmaceutical companies to develop therapies for these underserved patient populations. Advances in gene therapies, biologics, and precision medicine are creating new opportunities to address complex diseases, offering hope for patients with previously untreatable conditions.
  • Neurological Disorders: The neurological disorder segment is another key area of growth for the NME drug market. Diseases such as Alzheimer's, Parkinson's, and multiple sclerosis are gaining increased attention from researchers and drug developers. The aging global population and the lack of effective treatments for many neurological conditions create a substantial market opportunity. Innovations in gene therapy, biologics, and targeted small molecules are driving growth in this sector.
  • Infectious Diseases: The rise in antimicrobial resistance and the growing demand for new treatments for infectious diseases create significant opportunities in the NME drug market. With the COVID-19 pandemic underscoring the importance of rapid drug development and global collaboration, the focus on developing NMEs for infectious diseases has intensified. Companies are exploring new mechanisms of action, such as antiviral and antibacterial-resistant drugs, to address emerging global health threats.
  • Personalized Medicine and Precision Therapies: The increasing shift toward personalized medicine presents a significant growth opportunity for the NME drug market. With the help of biomarkers, genetic testing, and AI-driven tools, pharmaceutical companies can develop tailored therapies that address individual patient profiles. This approach is particularly promising in oncology, rare diseases, and autoimmune conditions. Personalized medicine allows for more effective treatments with fewer side effects, providing long-term value for both patients and healthcare systems.

The strategic growth opportunities in the NME drug market are driven by the demand for innovative therapies in oncology, rare diseases, neurological disorders, and infectious diseases. Advances in personalized medicine and precision therapies are expanding treatment options and improving patient outcomes. These opportunities are reshaping the pharmaceutical industry, driving innovation and investment in the development of next-generation treatments that address complex and previously untreatable diseases.

New Molecular Entity Drug Market Driver and Challenges

The NME drug market is influenced by a variety of drivers and challenges, which include technological, economic, and regulatory factors.

The factors responsible for driving the new molecular entity drug market include:

1. Advancements in Biotechnology: Biotechnology innovations, particularly in gene editing and biologics, are driving the NME drug market forward. New technologies such as CRISPR and RNA-based therapies are enabling the development of novel treatments for complex diseases, paving the way for next-generation drugs. These advancements are helping pharmaceutical companies create more effective, targeted therapies that improve patient outcomes.

2. Increased Research and Development Investment: Significant investment in research and development (R&D) is fueling innovation in the NME drug market. Pharmaceutical companies, particularly biotech firms, are investing heavily in exploring new drug discovery approaches, clinical trials, and collaboration with research institutions. This increased investment is accelerating the development of novel treatments and expanding the drug pipeline.

3. Regulatory Support for Innovation: Regulatory agencies in key markets are supporting the development of innovative drugs through expedited approval pathways, such as the FDA's Breakthrough Therapy Designation and the EMA's PRIME program. These regulatory measures help reduce time-to-market for NME drugs, providing faster access to life-saving treatments for patients in need.

4. Growing Global Healthcare Demand: The increasing demand for healthcare services, driven by aging populations, chronic disease burdens, and emerging health threats like infectious diseases, is fueling the demand for new drugs. The global healthcare market is expanding, and NME drugs are at the forefront of meeting these needs, especially in underserved regions.

5. Collaborations and Partnerships: Collaborations between pharmaceutical companies, academic institutions, and healthcare providers are enabling faster drug discovery and development. By pooling resources and expertise, stakeholders can accelerate clinical trials, share research data, and bring new drugs to market more efficiently. These partnerships are essential for advancing the NME drug pipeline.

Challenges in the new molecular entity drug market are:

1. High Development Costs: The development of new molecular entities is expensive and time-consuming. Clinical trials, regulatory approvals, and the need for specialized expertise all contribute to the high costs associated with developing NMEs. This can limit the ability of smaller companies to compete and may delay the introduction of new treatments.

2. Market Access Barriers: Despite regulatory approvals, market access barriers, including pricing and reimbursement challenges, can hinder the availability of NME drugs. In many cases, the high cost of innovative therapies can limit their affordability and accessibility, particularly in low- and middle-income countries.

3. Complexity of Clinical Trials: The complexity of designing and conducting clinical trials, particularly for rare diseases and personalized medicine, presents a significant challenge in the NME drug market. Recruiting patients, managing diverse study populations, and ensuring rigorous trial methodologies require significant resources and time.

While drivers such as technological advancements, R&D investment, and regulatory support are fueling growth in the NME drug market, challenges like high costs, market access barriers, and clinical trial complexities remain key obstacles. Overcoming these challenges will be crucial to ensuring continued innovation and accessibility in the NME drug market.

List of New Molecular Entity Drug Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies new molecular entity drug companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the new molecular entity drug companies profiled in this report include-

  • UCB
  • Otsuka Pharmaceutical
  • Eli Lilly
  • Genentech
  • Eisai
  • Biogen
  • Menarini Group
  • GSK
  • Chest
  • Travere

New Molecular Entity Drug Market by Segment

The study includes a forecast for the global new molecular entity drug market by type, application, and region.

New Molecular Entity Drug Market by Type [Value from 2019 to 2031]:

  • Antibody
  • Polypeptide
  • Small Molecule Drug
  • Other

New Molecular Entity Drug Market by Application [Value from 2019 to 2031]:

  • Hospitals
  • Clinics

New Molecular Entity Drug Market by Region [Value from 2019 to 2031]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

Country Wise Outlook for the New Molecular Entity Drug Market

The new molecular entity drug market has been undergoing significant growth due to advancements in biotechnology, precision medicine, and an increased understanding of disease mechanisms. These drugs are critical in treating conditions that have limited therapeutic options. With an emphasis on personalized treatment, the market in countries like the United States, China, Germany, India, and Japan is experiencing rapid innovation. Regulatory agencies, industry collaborations, and research institutions are playing pivotal roles in accelerating the discovery and approval of these groundbreaking treatments, impacting both healthcare systems and patient outcomes.

  • United States: The United States remains at the forefront of NME drug development, with a significant number of new molecular entities being approved by the U.S. Food and Drug Administration (FDA). Key therapeutic areas such as oncology, immunology, and neurology are seeing rapid advancements in NME treatments. The FDA's expedited approval pathways, such as Breakthrough Therapy and Accelerated Approval, have been instrumental in bringing innovative treatments to market faster. Additionally, the growing emphasis on personalized medicine and biologics is driving innovation in the U.S. NME drug market, with many biotech firms focusing on targeted therapies for rare diseases and cancer.
  • China: China's pharmaceutical industry has seen substantial growth in recent years, with a strong focus on developing and commercializing new molecular entities. The country has made significant strides in regulatory reform, with the China National Medical Products Administration (NMPA) accelerating drug approval processes, leading to an increase in NME drug launches. Areas like oncology, diabetes, and cardiovascular diseases are seeing increasing numbers of new drugs entering the market. China is also becoming a hub for clinical trials, with multinational pharmaceutical companies leveraging the country's vast population to test new drugs, facilitating faster approval and commercialization.
  • Germany: Germany, as a leader in Europe, has been making notable progress in the NME drug market, particularly in oncology, immunology, and rare diseases. The country's robust healthcare infrastructure, strong regulatory environment, and innovative biotech companies have contributed to the rapid development of new drugs. The European Medicines Agency (EMA) has played a vital role in expediting approvals within the EU, with Germany benefiting from these initiatives. Moreover, Germany's emphasis on precision medicine and its investment in research collaborations with academic institutions and global pharmaceutical companies is helping shape the future of NME drug development in the region.
  • India: The Indian NME drug market is seeing rapid growth due to an increasing focus on research and development (R&D) and the country's growing biotech ecosystem. Indian pharmaceutical companies are increasingly involved in the development of new molecular entities, particularly for treating infectious diseases, cancer, and diabetes. The Indian government's initiatives, such as the "Pharma Vision 2020," aim to boost the country's pharmaceutical R&D capabilities. Additionally, India is playing a crucial role in the global supply chain, with a growing number of clinical trials being conducted in the country, contributing to NME drug discovery and development.
  • Japan: Japan is a key player in the NME drug market, with strong government support for pharmaceutical innovation. The Japanese Ministry of Health, Labour, and Welfare (MHLW) has created a favorable environment for drug approval with initiatives such as the Sakigake Designation System, which accelerates the development of innovative drugs. Japan's aging population is a key driver for the demand for NME drugs, especially in the fields of oncology, neurodegenerative diseases, and cardiovascular disorders. Additionally, Japan is home to several global pharmaceutical companies that are investing in cutting-edge research and clinical trials to develop new drugs that address unmet medical needs.

Features of the Global New Molecular Entity Drug Market

  • Market Size Estimates: New molecular entity drug market size estimation in terms of value ($B).
  • Trend and Forecast Analysis: Market trends (2019 to 2024) and forecast (2025 to 2031) by various segments and regions.
  • Segmentation Analysis: New molecular entity drug market size by type, application, and region in terms of value ($B).
  • Regional Analysis: New molecular entity drug market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
  • Growth Opportunities: Analysis of growth opportunities in different types, applications, and regions for the new molecular entity drug market.
  • Strategic Analysis: This includes M&A, new product development, and competitive landscape of the new molecular entity drug market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the new molecular entity drug market by type (antibody, polypeptide, small molecule drug, and other), application (hospitals and clinics), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Market Overview

  • 2.1 Background and Classifications
  • 2.2 Supply Chain

3. Market Trends & Forecast Analysis

  • 3.1 Macroeconomic Trends and Forecasts
  • 3.2 Industry Drivers and Challenges
  • 3.3 PESTLE Analysis
  • 3.4 Patent Analysis
  • 3.5 Regulatory Environment

4. Global New Molecular Entity Drug Market by Type

  • 4.1 Overview
  • 4.2 Attractiveness Analysis by Type
  • 4.3 Antibody: Trends and Forecast (2019-2031)
  • 4.4 Polypeptide: Trends and Forecast (2019-2031)
  • 4.5 Small Molecule Drug: Trends and Forecast (2019-2031)
  • 4.6 Other: Trends and Forecast (2019-2031)

5. Global New Molecular Entity Drug Market by Application

  • 5.1 Overview
  • 5.2 Attractiveness Analysis by Application
  • 5.3 Hospitals: Trends and Forecast (2019-2031)
  • 5.4 Clinics: Trends and Forecast (2019-2031)

6. Regional Analysis

  • 6.1 Overview
  • 6.2 Global New Molecular Entity Drug Market by Region

7. North American New Molecular Entity Drug Market

  • 7.1 Overview
  • 7.2 North American New Molecular Entity Drug Market by Type
  • 7.3 North American New Molecular Entity Drug Market by Application
  • 7.4 United States New Molecular Entity Drug Market
  • 7.5 Mexican New Molecular Entity Drug Market
  • 7.6 Canadian New Molecular Entity Drug Market

8. European New Molecular Entity Drug Market

  • 8.1 Overview
  • 8.2 European New Molecular Entity Drug Market by Type
  • 8.3 European New Molecular Entity Drug Market by Application
  • 8.4 German New Molecular Entity Drug Market
  • 8.5 French New Molecular Entity Drug Market
  • 8.6 Spanish New Molecular Entity Drug Market
  • 8.7 Italian New Molecular Entity Drug Market
  • 8.8 United Kingdom New Molecular Entity Drug Market

9. APAC New Molecular Entity Drug Market

  • 9.1 Overview
  • 9.2 APAC New Molecular Entity Drug Market by Type
  • 9.3 APAC New Molecular Entity Drug Market by Application
  • 9.4 Japanese New Molecular Entity Drug Market
  • 9.5 Indian New Molecular Entity Drug Market
  • 9.6 Chinese New Molecular Entity Drug Market
  • 9.7 South Korean New Molecular Entity Drug Market
  • 9.8 Indonesian New Molecular Entity Drug Market

10. ROW New Molecular Entity Drug Market

  • 10.1 Overview
  • 10.2 ROW New Molecular Entity Drug Market by Type
  • 10.3 ROW New Molecular Entity Drug Market by Application
  • 10.4 Middle Eastern New Molecular Entity Drug Market
  • 10.5 South American New Molecular Entity Drug Market
  • 10.6 African New Molecular Entity Drug Market

11. Competitor Analysis

  • 11.1 Product Portfolio Analysis
  • 11.2 Operational Integration
  • 11.3 Porter's Five Forces Analysis
    • Competitive Rivalry
    • Bargaining Power of Buyers
    • Bargaining Power of Suppliers
    • Threat of Substitutes
    • Threat of New Entrants
  • 11.4 Market Share Analysis

12. Opportunities & Strategic Analysis

  • 12.1 Value Chain Analysis
  • 12.2 Growth Opportunity Analysis
    • 12.2.1 Growth Opportunities by Type
    • 12.2.2 Growth Opportunities by Application
  • 12.3 Emerging Trends in the Global New Molecular Entity Drug Market
  • 12.4 Strategic Analysis
    • 12.4.1 New Product Development
    • 12.4.2 Certification and Licensing
    • 12.4.3 Mergers, Acquisitions, Agreements, Collaborations, and Joint Ventures

13. Company Profiles of the Leading Players Across the Value Chain

  • 13.1 Competitive Analysis
  • 13.2 UCB
    • Company Overview
    • New Molecular Entity Drug Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 13.3 Otsuka Pharmaceutical
    • Company Overview
    • New Molecular Entity Drug Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 13.4 Eli Lilly
    • Company Overview
    • New Molecular Entity Drug Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 13.5 Genentech
    • Company Overview
    • New Molecular Entity Drug Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 13.6 Eisai
    • Company Overview
    • New Molecular Entity Drug Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 13.7 Biogen
    • Company Overview
    • New Molecular Entity Drug Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 13.8 Menarini Group
    • Company Overview
    • New Molecular Entity Drug Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 13.9 GSK
    • Company Overview
    • New Molecular Entity Drug Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 13.10 Chest
    • Company Overview
    • New Molecular Entity Drug Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 13.11 Travere
    • Company Overview
    • New Molecular Entity Drug Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing

14. Appendix

  • 14.1 List of Figures
  • 14.2 List of Tables
  • 14.3 Research Methodology
  • 14.4 Disclaimer
  • 14.5 Copyright
  • 14.6 Abbreviations and Technical Units
  • 14.7 About Us
  • 14.8 Contact Us

List of Figures

  • Figure 1.1: Trends and Forecast for the Global New Molecular Entity Drug Market
  • Figure 2.1: Usage of New Molecular Entity Drug Market
  • Figure 2.2: Classification of the Global New Molecular Entity Drug Market
  • Figure 2.3: Supply Chain of the Global New Molecular Entity Drug Market
  • Figure 3.1: Trends of the Global GDP Growth Rate
  • Figure 3.2: Trends of the Global Population Growth Rate
  • Figure 3.3: Trends of the Global Inflation Rate
  • Figure 3.4: Trends of the Global Unemployment Rate
  • Figure 3.5: Trends of the Regional GDP Growth Rate
  • Figure 3.6: Trends of the Regional Population Growth Rate
  • Figure 3.7: Trends of the Regional Inflation Rate
  • Figure 3.8: Trends of the Regional Unemployment Rate
  • Figure 3.9: Trends of Regional Per Capita Income
  • Figure 3.10: Forecast for the Global GDP Growth Rate
  • Figure 3.11: Forecast for the Global Population Growth Rate
  • Figure 3.12: Forecast for the Global Inflation Rate
  • Figure 3.13: Forecast for the Global Unemployment Rate
  • Figure 3.14: Forecast for the Regional GDP Growth Rate
  • Figure 3.15: Forecast for the Regional Population Growth Rate
  • Figure 3.16: Forecast for the Regional Inflation Rate
  • Figure 3.17: Forecast for the Regional Unemployment Rate
  • Figure 3.18: Forecast for Regional Per Capita Income
  • Figure 3.19: Driver and Challenges of the New Molecular Entity Drug Market
  • Figure 4.1: Global New Molecular Entity Drug Market by Type in 2019, 2024, and 2031
  • Figure 4.2: Trends of the Global New Molecular Entity Drug Market ($B) by Type
  • Figure 4.3: Forecast for the Global New Molecular Entity Drug Market ($B) by Type
  • Figure 4.4: Trends and Forecast for Antibody in the Global New Molecular Entity Drug Market (2019-2031)
  • Figure 4.5: Trends and Forecast for Polypeptide in the Global New Molecular Entity Drug Market (2019-2031)
  • Figure 4.6: Trends and Forecast for Small Molecule Drug in the Global New Molecular Entity Drug Market (2019-2031)
  • Figure 4.7: Trends and Forecast for Other in the Global New Molecular Entity Drug Market (2019-2031)
  • Figure 5.1: Global New Molecular Entity Drug Market by Application in 2019, 2024, and 2031
  • Figure 5.2: Trends of the Global New Molecular Entity Drug Market ($B) by Application
  • Figure 5.3: Forecast for the Global New Molecular Entity Drug Market ($B) by Application
  • Figure 5.4: Trends and Forecast for Hospitals in the Global New Molecular Entity Drug Market (2019-2031)
  • Figure 5.5: Trends and Forecast for Clinics in the Global New Molecular Entity Drug Market (2019-2031)
  • Figure 6.1: Trends of the Global New Molecular Entity Drug Market ($B) by Region (2019-2024)
  • Figure 6.2: Forecast for the Global New Molecular Entity Drug Market ($B) by Region (2025-2031)
  • Figure 7.1: Trends and Forecast for the North American New Molecular Entity Drug Market (2019-2031)
  • Figure 7.2: North American New Molecular Entity Drug Market by Type in 2019, 2024, and 2031
  • Figure 7.3: Trends of the North American New Molecular Entity Drug Market ($B) by Type (2019-2024)
  • Figure 7.4: Forecast for the North American New Molecular Entity Drug Market ($B) by Type (2025-2031)
  • Figure 7.5: North American New Molecular Entity Drug Market by Application in 2019, 2024, and 2031
  • Figure 7.6: Trends of the North American New Molecular Entity Drug Market ($B) by Application (2019-2024)
  • Figure 7.7: Forecast for the North American New Molecular Entity Drug Market ($B) by Application (2025-2031)
  • Figure 7.8: Trends and Forecast for the United States New Molecular Entity Drug Market ($B) (2019-2031)
  • Figure 7.9: Trends and Forecast for the Mexican New Molecular Entity Drug Market ($B) (2019-2031)
  • Figure 7.10: Trends and Forecast for the Canadian New Molecular Entity Drug Market ($B) (2019-2031)
  • Figure 8.1: Trends and Forecast for the European New Molecular Entity Drug Market (2019-2031)
  • Figure 8.2: European New Molecular Entity Drug Market by Type in 2019, 2024, and 2031
  • Figure 8.3: Trends of the European New Molecular Entity Drug Market ($B) by Type (2019-2024)
  • Figure 8.4: Forecast for the European New Molecular Entity Drug Market ($B) by Type (2025-2031)
  • Figure 8.5: European New Molecular Entity Drug Market by Application in 2019, 2024, and 2031
  • Figure 8.6: Trends of the European New Molecular Entity Drug Market ($B) by Application (2019-2024)
  • Figure 8.7: Forecast for the European New Molecular Entity Drug Market ($B) by Application (2025-2031)
  • Figure 8.8: Trends and Forecast for the German New Molecular Entity Drug Market ($B) (2019-2031)
  • Figure 8.9: Trends and Forecast for the French New Molecular Entity Drug Market ($B) (2019-2031)
  • Figure 8.10: Trends and Forecast for the Spanish New Molecular Entity Drug Market ($B) (2019-2031)
  • Figure 8.11: Trends and Forecast for the Italian New Molecular Entity Drug Market ($B) (2019-2031)
  • Figure 8.12: Trends and Forecast for the United Kingdom New Molecular Entity Drug Market ($B) (2019-2031)
  • Figure 9.1: Trends and Forecast for the APAC New Molecular Entity Drug Market (2019-2031)
  • Figure 9.2: APAC New Molecular Entity Drug Market by Type in 2019, 2024, and 2031
  • Figure 9.3: Trends of the APAC New Molecular Entity Drug Market ($B) by Type (2019-2024)
  • Figure 9.4: Forecast for the APAC New Molecular Entity Drug Market ($B) by Type (2025-2031)
  • Figure 9.5: APAC New Molecular Entity Drug Market by Application in 2019, 2024, and 2031
  • Figure 9.6: Trends of the APAC New Molecular Entity Drug Market ($B) by Application (2019-2024)
  • Figure 9.7: Forecast for the APAC New Molecular Entity Drug Market ($B) by Application (2025-2031)
  • Figure 9.8: Trends and Forecast for the Japanese New Molecular Entity Drug Market ($B) (2019-2031)
  • Figure 9.9: Trends and Forecast for the Indian New Molecular Entity Drug Market ($B) (2019-2031)
  • Figure 9.10: Trends and Forecast for the Chinese New Molecular Entity Drug Market ($B) (2019-2031)
  • Figure 9.11: Trends and Forecast for the South Korean New Molecular Entity Drug Market ($B) (2019-2031)
  • Figure 9.12: Trends and Forecast for the Indonesian New Molecular Entity Drug Market ($B) (2019-2031)
  • Figure 10.1: Trends and Forecast for the ROW New Molecular Entity Drug Market (2019-2031)
  • Figure 10.2: ROW New Molecular Entity Drug Market by Type in 2019, 2024, and 2031
  • Figure 10.3: Trends of the ROW New Molecular Entity Drug Market ($B) by Type (2019-2024)
  • Figure 10.4: Forecast for the ROW New Molecular Entity Drug Market ($B) by Type (2025-2031)
  • Figure 10.5: ROW New Molecular Entity Drug Market by Application in 2019, 2024, and 2031
  • Figure 10.6: Trends of the ROW New Molecular Entity Drug Market ($B) by Application (2019-2024)
  • Figure 10.7: Forecast for the ROW New Molecular Entity Drug Market ($B) by Application (2025-2031)
  • Figure 10.8: Trends and Forecast for the Middle Eastern New Molecular Entity Drug Market ($B) (2019-2031)
  • Figure 10.9: Trends and Forecast for the South American New Molecular Entity Drug Market ($B) (2019-2031)
  • Figure 10.10: Trends and Forecast for the African New Molecular Entity Drug Market ($B) (2019-2031)
  • Figure 11.1: Porter's Five Forces Analysis of the Global New Molecular Entity Drug Market
  • Figure 11.2: Market Share (%) of Top Players in the Global New Molecular Entity Drug Market (2024)
  • Figure 12.1: Growth Opportunities for the Global New Molecular Entity Drug Market by Type
  • Figure 12.2: Growth Opportunities for the Global New Molecular Entity Drug Market by Application
  • Figure 12.3: Growth Opportunities for the Global New Molecular Entity Drug Market by Region
  • Figure 12.4: Emerging Trends in the Global New Molecular Entity Drug Market

List of Tables

  • Table 1.1: Growth Rate (%, 2023-2024) and CAGR (%, 2025-2031) of the New Molecular Entity Drug Market by Type and Application
  • Table 1.2: Attractiveness Analysis for the New Molecular Entity Drug Market by Region
  • Table 1.3: Global New Molecular Entity Drug Market Parameters and Attributes
  • Table 3.1: Trends of the Global New Molecular Entity Drug Market (2019-2024)
  • Table 3.2: Forecast for the Global New Molecular Entity Drug Market (2025-2031)
  • Table 4.1: Attractiveness Analysis for the Global New Molecular Entity Drug Market by Type
  • Table 4.2: Market Size and CAGR of Various Type in the Global New Molecular Entity Drug Market (2019-2024)
  • Table 4.3: Market Size and CAGR of Various Type in the Global New Molecular Entity Drug Market (2025-2031)
  • Table 4.4: Trends of Antibody in the Global New Molecular Entity Drug Market (2019-2024)
  • Table 4.5: Forecast for Antibody in the Global New Molecular Entity Drug Market (2025-2031)
  • Table 4.6: Trends of Polypeptide in the Global New Molecular Entity Drug Market (2019-2024)
  • Table 4.7: Forecast for Polypeptide in the Global New Molecular Entity Drug Market (2025-2031)
  • Table 4.8: Trends of Small Molecule Drug in the Global New Molecular Entity Drug Market (2019-2024)
  • Table 4.9: Forecast for Small Molecule Drug in the Global New Molecular Entity Drug Market (2025-2031)
  • Table 4.10: Trends of Other in the Global New Molecular Entity Drug Market (2019-2024)
  • Table 4.11: Forecast for Other in the Global New Molecular Entity Drug Market (2025-2031)
  • Table 5.1: Attractiveness Analysis for the Global New Molecular Entity Drug Market by Application
  • Table 5.2: Market Size and CAGR of Various Application in the Global New Molecular Entity Drug Market (2019-2024)
  • Table 5.3: Market Size and CAGR of Various Application in the Global New Molecular Entity Drug Market (2025-2031)
  • Table 5.4: Trends of Hospitals in the Global New Molecular Entity Drug Market (2019-2024)
  • Table 5.5: Forecast for Hospitals in the Global New Molecular Entity Drug Market (2025-2031)
  • Table 5.6: Trends of Clinics in the Global New Molecular Entity Drug Market (2019-2024)
  • Table 5.7: Forecast for Clinics in the Global New Molecular Entity Drug Market (2025-2031)
  • Table 6.1: Market Size and CAGR of Various Regions in the Global New Molecular Entity Drug Market (2019-2024)
  • Table 6.2: Market Size and CAGR of Various Regions in the Global New Molecular Entity Drug Market (2025-2031)
  • Table 7.1: Trends of the North American New Molecular Entity Drug Market (2019-2024)
  • Table 7.2: Forecast for the North American New Molecular Entity Drug Market (2025-2031)
  • Table 7.3: Market Size and CAGR of Various Type in the North American New Molecular Entity Drug Market (2019-2024)
  • Table 7.4: Market Size and CAGR of Various Type in the North American New Molecular Entity Drug Market (2025-2031)
  • Table 7.5: Market Size and CAGR of Various Application in the North American New Molecular Entity Drug Market (2019-2024)
  • Table 7.6: Market Size and CAGR of Various Application in the North American New Molecular Entity Drug Market (2025-2031)
  • Table 7.7: Trends and Forecast for the United States New Molecular Entity Drug Market (2019-2031)
  • Table 7.8: Trends and Forecast for the Mexican New Molecular Entity Drug Market (2019-2031)
  • Table 7.9: Trends and Forecast for the Canadian New Molecular Entity Drug Market (2019-2031)
  • Table 8.1: Trends of the European New Molecular Entity Drug Market (2019-2024)
  • Table 8.2: Forecast for the European New Molecular Entity Drug Market (2025-2031)
  • Table 8.3: Market Size and CAGR of Various Type in the European New Molecular Entity Drug Market (2019-2024)
  • Table 8.4: Market Size and CAGR of Various Type in the European New Molecular Entity Drug Market (2025-2031)
  • Table 8.5: Market Size and CAGR of Various Application in the European New Molecular Entity Drug Market (2019-2024)
  • Table 8.6: Market Size and CAGR of Various Application in the European New Molecular Entity Drug Market (2025-2031)
  • Table 8.7: Trends and Forecast for the German New Molecular Entity Drug Market (2019-2031)
  • Table 8.8: Trends and Forecast for the French New Molecular Entity Drug Market (2019-2031)
  • Table 8.9: Trends and Forecast for the Spanish New Molecular Entity Drug Market (2019-2031)
  • Table 8.10: Trends and Forecast for the Italian New Molecular Entity Drug Market (2019-2031)
  • Table 8.11: Trends and Forecast for the United Kingdom New Molecular Entity Drug Market (2019-2031)
  • Table 9.1: Trends of the APAC New Molecular Entity Drug Market (2019-2024)
  • Table 9.2: Forecast for the APAC New Molecular Entity Drug Market (2025-2031)
  • Table 9.3: Market Size and CAGR of Various Type in the APAC New Molecular Entity Drug Market (2019-2024)
  • Table 9.4: Market Size and CAGR of Various Type in the APAC New Molecular Entity Drug Market (2025-2031)
  • Table 9.5: Market Size and CAGR of Various Application in the APAC New Molecular Entity Drug Market (2019-2024)
  • Table 9.6: Market Size and CAGR of Various Application in the APAC New Molecular Entity Drug Market (2025-2031)
  • Table 9.7: Trends and Forecast for the Japanese New Molecular Entity Drug Market (2019-2031)
  • Table 9.8: Trends and Forecast for the Indian New Molecular Entity Drug Market (2019-2031)
  • Table 9.9: Trends and Forecast for the Chinese New Molecular Entity Drug Market (2019-2031)
  • Table 9.10: Trends and Forecast for the South Korean New Molecular Entity Drug Market (2019-2031)
  • Table 9.11: Trends and Forecast for the Indonesian New Molecular Entity Drug Market (2019-2031)
  • Table 10.1: Trends of the ROW New Molecular Entity Drug Market (2019-2024)
  • Table 10.2: Forecast for the ROW New Molecular Entity Drug Market (2025-2031)
  • Table 10.3: Market Size and CAGR of Various Type in the ROW New Molecular Entity Drug Market (2019-2024)
  • Table 10.4: Market Size and CAGR of Various Type in the ROW New Molecular Entity Drug Market (2025-2031)
  • Table 10.5: Market Size and CAGR of Various Application in the ROW New Molecular Entity Drug Market (2019-2024)
  • Table 10.6: Market Size and CAGR of Various Application in the ROW New Molecular Entity Drug Market (2025-2031)
  • Table 10.7: Trends and Forecast for the Middle Eastern New Molecular Entity Drug Market (2019-2031)
  • Table 10.8: Trends and Forecast for the South American New Molecular Entity Drug Market (2019-2031)
  • Table 10.9: Trends and Forecast for the African New Molecular Entity Drug Market (2019-2031)
  • Table 11.1: Product Mapping of New Molecular Entity Drug Suppliers Based on Segments
  • Table 11.2: Operational Integration of New Molecular Entity Drug Manufacturers
  • Table 11.3: Rankings of Suppliers Based on New Molecular Entity Drug Revenue
  • Table 12.1: New Product Launches by Major New Molecular Entity Drug Producers (2019-2024)
  • Table 12.2: Certification Acquired by Major Competitor in the Global New Molecular Entity Drug Market